Leukemia - Table of Contents alert Volume 28 Issue 7

If you are unable to see the message below, click here to view.

Advertisement BD FACSCanto™ has 10-color capability. Reliable performance, accuracy, and ease of use make the latest BD FACSCanto System a perfect 10 for today's busy clinical labs. Learn how you can achieve dependable outcomes while speeding workflow and reducing training requirements with clinical multi-color flow cytometry systems from BD Biosciences. bdbiosciences.com/go/canto TABLE OF CONTENTS Volume 28, Issue 7 (July 2014) In this issue Leading Article How To Manage... Spotlight Review Review Concise Review Original Articles Letters to the Editor Also new AOP Sign up for e-alerts Recommend to your library Web feed Follow on Twitter Subscribe Advertisement NEW DEALS: Lab equipment and services Browse our library of savings and information! Check Marketplace first  VISIT MARKETPLACE TODAY    Leading Article Top A role for oleoylethanolamide in chronic lymphocytic leukemia M Masoodi, E Lee, M Eiden, A Bahlo, Y Shi, R B Ceddia, C Baccei, P Prasit and D E Spaner Leukemia 2014 28: 1381-1387; advance online publication, January 13, 2014; 10.1038/leu.2014.10 Abstract | Full Text How To Manage... Top How we manage follicular lymphoma OPEN W Hiddemann and B D Cheson Leukemia 2014 28: 1388-1395; advance online publication, February 28, 2014; 10.1038/leu.2014.91 Abstract | Full Text Spotlight Review Top SPOTLIGHT ON EPIGENETICS IN HEMATOLOGIC MALIGNANCIES Chromatin modifiers and the promise of epigenetic therapy in acute leukemia OPEN S M Greenblatt and S D Nimer Leukemia 2014 28: 1396-1406; advance online publication, March 10, 2014; 10.1038/leu.2014.94 Abstract | Full Text Review Top An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms A Tefferi, J Thiele, A M Vannucchi and T Barbui Leukemia 2014 28: 1407-1413; advance online publication, January 20, 2014; 10.1038/leu.2014.35 Abstract | Full Text Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities S Fulda Leukemia 2014 28: 1414-1422; advance online publication, February 3, 2014; 10.1038/leu.2014.56 Abstract | Full Text Concise Review Top Update on second primary malignancies in multiple myeloma: a focused review O Landgren and S Mailankody Leukemia 2014 28: 1423-1426; advance online publication, January 14, 2014; 10.1038/leu.2014.22 Abstract | Full Text Original Articles Top MOLECULAR TARGETS FOR THERAPY Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia M-P Garcia-Cuellar, E Füller, E Mäthner, C Breitinger, K Hetzner, L Zeitlmann, A Borkhardt and R K Slany Leukemia 2014 28: 1427-1435; advance online publication, January 21, 2014; 10.1038/leu.2014.40 Abstract | Full Text ACUTE LEUKEMIAS PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway J Zhou, J Wu, B Li, D Liu, J Yu, X Yan, S Zheng, J Wang, L Zhang, L Zhang, F He, Q Li, A Chen, Y Zhang, X Zhao, Y Guan, X Zhao, J Yan, J Ni, M A Nobrega, B Löwenberg, R Delwel, P J M Valk, A Kumar, L Xie, D G Tenen, G Huang and Q-f Wang Leukemia 2014 28: 1436-1448; advance online publication, December 26, 2013; 10.1038/leu.2013.384 Abstract | Full Text High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome M-T Krauth, C Eder, T Alpermann, U Bacher, N Nadarajah, W Kern, C Haferlach, T Haferlach and S Schnittger Leukemia 2014 28: 1449-1458; advance online publication, January 9, 2014; 10.1038/leu.2014.4 Abstract | Full Text Expression of myeloperoxidase in acute myeloid leukemia blasts mirrors the distinct DNA methylation pattern involving the downregulation of DNA methyltransferase DNMT3B H Itonaga, D Imanishi, Y-F Wong, S Sato, K Ando, Y Sawayama, D Sasaki, K Tsuruda, H Hasegawa, Y Imaizumi, J Taguchi, H Tsushima, S Yoshida, T Fukushima, T Hata, Y Moriuchi, K Yanagihara and Y Miyazaki Leukemia 2014 28: 1459-1466; advance online publication, January 10, 2014; 10.1038/leu.2014.15 Abstract | Full Text Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031 K R Schultz, A Carroll, N A Heerema, W P Bowman, A Aledo, W B Slayton, H Sather, M Devidas, H W Zheng, S M Davies, P S Gaynon, M Trigg, R Rutledge, D Jorstad, N Winick, M J Borowitz, S P Hunger, W L Carroll and B Camitta from the Children’s Oncology Group Leukemia 2014 28: 1467-1471; advance online publication, January 20, 2014; 10.1038/leu.2014.30 Abstract | Full Text CHRONIC MYELOPROLIFERATIVE NEOPLASIAS CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons A Tefferi, T L Lasho, C M Finke, R A Knudson, R Ketterling, C H Hanson, M Maffioli, D Caramazza, F Passamonti and A Pardanani Leukemia 2014 28: 1472-1477; advance online publication, January 9, 2014; 10.1038/leu.2014.3 Abstract | Full Text MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure M Agrawal, B Hanfstein, P Erben, D Wolf, T Ernst, A Fabarius, S Saussele, D Purkayastha, R C Woodman, W-K Hofmann, R Hehlmann, A Hochhaus and M C Müller Leukemia 2014 28: 1478-1485; advance online publication, January 10, 2014; 10.1038/leu.2014.6 Abstract | Full Text Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis A Tabarroki, D J Lindner, V Visconte, L Zhang, H J Rogers, Y Parker, H K Duong, A Lichtin, M E Kalaycio, M A Sekeres, S E Mountantonakis, G A Heresi and R V Tiu Leukemia 2014 28: 1486-1493; advance online publication, January 10, 2014; 10.1038/leu.2014.5 Abstract | Full Text CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients OPEN A Tefferi, P Guglielmelli, T L Lasho, G Rotunno, C Finke, C Mannarelli, A A Belachew, A Pancrazzi, E A Wassie, R P Ketterling, C A Hanson, A Pardanani and A M Vannucchi Leukemia 2014 28: 1494-1500; advance online publication, February 5, 2014; 10.1038/leu.2014.57 Abstract | Full Text CHRONIC LYMPHOCYTIC LEUKEMIA The CD37-targeted antibody–drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model K A Beckwith, F W Frissora, M R Stefanovski, W H Towns, C Cheney, X Mo, J Deckert, C M Croce, J M Flynn, L A Andritsos, J A Jones, K J Maddocks, G Lozanski, J C Byrd and N Muthusamy Leukemia 2014 28: 1501-1510; advance online publication, January 21, 2014; 10.1038/leu.2014.32 Abstract | Full Text CYTOGENETICS AND MOLECULAR GENETICS High hyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): cytogenetic features, clinical characteristics and outcome L Chilton, G Buck, C J Harrison, R P Ketterling, J M Rowe, M S Tallman, A H Goldstone, A K Fielding and A V Moorman Leukemia 2014 28: 1511-1518; advance online publication, December 19, 2013; 10.1038/leu.2013.379 Abstract | Full Text MYELOMA Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma V Ramakrishnan, U Painuly, T Kimlinger, J Haug, S V Rajkumar and S Kumar Leukemia 2014 28: 1519-1528; advance online publication, January 9, 2014; 10.1038/leu.2014.2 Abstract | Full Text Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy OPEN J R Berenson, J D Hilger, O Yellin, R Dichmann, D Patel-Donnelly, R V Boccia, A Bessudo, L Stampleman, D Gravenor, S Eshaghian, Y Nassir, R A Swift and R A Vescio Leukemia 2014 28: 1529-1536; advance online publication, January 16, 2014; 10.1038/leu.2014.27 Abstract | Full Text Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the National Health and Nutritional Examination Survey O Landgren, B I Graubard, J A Katzmann, R A Kyle, I Ahmadizadeh, R Clark, S K Kumar, A Dispenzieri, A J Greenberg, T M Therneau, L J Melton, III, N Caporaso, N Korde, M Roschewski, R Costello, G M McQuillan and S V Rajkumar Leukemia 2014 28: 1537-1542; advance online publication, January 20, 2014; 10.1038/leu.2014.34 Abstract | Full Text Letters to the Editor Top Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia F Ravandi, C Arana Yi, J E Cortes, M Levis, S Faderl, G Garcia-Manero, E Jabbour, M Konopleva, S O'Brien, Z Estrov, G Borthakur, D Thomas, S Pierce, M Brandt, K Pratz, R Luthra, M Andreeff and H Kantarjian Leukemia 2014 28: 1543-1545; advance online publication, February 3, 2014; 10.1038/leu.2014.54 Full Text Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia K Matsuda, Y Nakazawa, C Iwashita, T Kurata, K Hirabayashi, S Saito, M Tanaka, K Yoshikawa, R Yanagisawa, K Sakashita, S Sasaki, T Honda and K Koike Leukemia 2014 28: 1545-1548; advance online publication, February 5, 2014; 10.1038/leu.2014.58 Full Text Serial exome analysis of disease progression in premalignant gammopathies OPEN S Zhao, M Choi, C Heuck, S Mane, B Barlogie, R P Lifton and M V Dhodapkar Leukemia 2014 28: 1548-1552; advance online publication, February 5, 2014; 10.1038/leu.2014.59 Full Text Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation V Panagiota, F Thol, B Markus, B Fehse, H Alchalby, A Badbaran, U Lehmann, C Koenecke, R Shahswar, A Chaturvedi, M Stadler, M Eder, G Göhring, M Koenigsmann, A Kloos, A Trummer, T Schroeder, G Kobbe, C Thiede, U Platzbecker, B Schlegelberger, H-H Kreipe, A Ganser, N Kröger and M Heuser Leukemia 2014 28: 1552-1555; advance online publication, February 7, 2014; 10.1038/leu.2014.66 Full Text Calreticulin mutation was rarely detected in patients with myelodysplastic syndrome H-A Hou, Y-Y Kuo, W-C Chou, P-H Chen and H-F Tien Leukemia 2014 28: 1555-1557; advance online publication, February 17, 2014; 10.1038/leu.2014.71 Full Text Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199 X Niu, G Wang, Y Wang, J T Caldwell, H Edwards, C Xie, J W Taub, C Li, H Lin and Y Ge Leukemia 2014 28: 1557-1560; advance online publication, February 17, 2014; 10.1038/leu.2014.72 Full Text Persistent polyclonal B-cell lymphocytosis: extensively proliferated CD27+IgM+IgD+ memory B cells with a distinctive immunophenotype M A Berkowska, C Grosserichter-Wagener, H J Adriaansen, D de Ridder, K P Mirani-Oostdijk, H J Agteresch, S Böttcher, A Orfao, J J M van Dongen and M C van Zelm Leukemia 2014 28: 1560-1564; advance online publication, February 19, 2014; 10.1038/leu.2014.77 Full Text Unique BHLHB3 overexpression in pediatric acute myeloid leukemia with t(6;11)(q27;q23) E A Coenen, C M Zwaan, J Stary, A Baruchel, V de Haas, R W Stam, D Reinhardt, G J L Kaspers, S T C J M Arentsen-Peters, C Meyer, R Marschalek, L L Nigro, M Dworzak, R Pieters and M M van den Heuvel-Eibrink Leukemia 2014 28: 1564-1568; advance online publication, February 24, 2014; 10.1038/leu.2014.82 Full Text Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact A Tefferi, T L Lasho, C Finke, A A Belachew, E A Wassie, R P Ketterling, C A Hanson and A Pardanani Leukemia 2014 28: 1568-1570; advance online publication, February 26, 2014; 10.1038/leu.2014.83 Full Text A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia M W Drummond, C Pocock, M Boissinot, J Mills, J Brown, P Cauchy, N C P Cross, S Hartley, J Kell, A Szubert, P N Cockerill and D T Bowen Leukemia 2014 28: 1570-1572; advance online publication, February 26, 2014; 10.1038/leu.2014.85 Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.